MedPath

Methadone Oxytocin Option

Early Phase 1
Completed
Conditions
Methadone Treatment
Substance Abuse
Opioid Dependence
Interventions
Drug: Saline Nasal Spray
Registration Number
NCT01728909
Lead Sponsor
University of California, San Francisco
Brief Summary

The purpose of the study is to examine the effects of intranasal oxytocin administration on social cognition in patients receiving methadone maintenance treatment (MMT), examine the effects of intranasal oxytocin administration on opioid craving and on the subjective effects of methadone, and examine the effects of intranasal oxytocin administration on implicit preferences for drug-related and social stimuli in patients receiving MMT.

Hypothesis 1: Patients will perform better on measures of social cognition (including affect recognition and recognition of sarcasm) after administration of oxytocin compared with placebo.

Hypothesis 2: Patients will demonstrate lower craving for opioids and greater subjective effects of methadone after administration of oxytocin compared with placebo.

Hypothesis 3: Patients will demonstrate increased implicit preferences for social stimuli and decreased implicit preferences for drug related stimuli after administration of oxytocin compared with placebo.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
64
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Saline Nasal SpraySaline Nasal SprayPlacebo Comparator
OxytocinOxytocin40 IU Oxytocin
Primary Outcome Measures
NameTimeMethod
Computerized Social Cognition TasksParticipants will complete 2 days of the study. These 2 days will be at least a week apart.

Participants will undergo computer tasks that measure social cognition, which include the TASIT, RMET, and the IAT. The TASIT measures the awareness of social inference, the RMET measures the ability to guess the emotions of others, and the IAT measures implicit associations.

Secondary Outcome Measures
NameTimeMethod
Craving QuestionnairesParticipants will complete 2 days of the study. These 2 days will be at least a week apart.

Participants are asked to rate their current symptoms and current craving levels and for different substances.

Trial Locations

Locations (1)

San Francisco VA Medical Center

🇺🇸

San Francisco, California, United States

San Francisco VA Medical Center
🇺🇸San Francisco, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.